Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Barclays PLC increased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 321.2% during the third quarter, HoldingsChannel.com reports. The firm owned 60,032 shares of the company’s stock after acquiring an additional 45,781 shares during the quarter. Barclays PLC’s holdings in Larimar Therapeutics were worth $393,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Quarry LP grew its holdings in shares of Larimar Therapeutics by 966.7% during the second quarter. Quarry LP now owns 8,000 shares of the company’s stock valued at $58,000 after buying an additional 7,250 shares during the last quarter. Quest Partners LLC boosted its position in shares of Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock valued at $60,000 after buying an additional 5,796 shares during the last quarter. Intech Investment Management LLC bought a new stake in Larimar Therapeutics in the 3rd quarter worth about $85,000. SG Americas Securities LLC purchased a new position in Larimar Therapeutics in the 3rd quarter worth about $94,000. Finally, XTX Topco Ltd bought a new position in Larimar Therapeutics during the 3rd quarter valued at about $100,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LRMR has been the subject of a number of research analyst reports. Wedbush initiated coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Larimar Therapeutics in a research note on Monday, December 16th. William Blair restated an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 19th. Finally, Oppenheimer began coverage on Larimar Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $26.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $20.43.

Larimar Therapeutics Price Performance

NASDAQ:LRMR opened at $3.34 on Friday. Larimar Therapeutics, Inc. has a one year low of $3.01 and a one year high of $13.68. The business has a fifty day moving average price of $5.26 and a 200-day moving average price of $6.96. The firm has a market capitalization of $213.13 million, a price-to-earnings ratio of -2.90 and a beta of 0.91.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.13. During the same period in the prior year, the business posted ($0.21) EPS. On average, equities research analysts expect that Larimar Therapeutics, Inc. will post -1.16 earnings per share for the current fiscal year.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.